Document is current
Any future updates will be listed below
-
Authors
Kanie, Keitaro https://orcid.org/0000-0002-9004-9857
Ito, Takeshi
Iguchi, Genzo
Matsumoto, Ryusaku https://orcid.org/0000-0002-7191-5326
Muguruma, Keiko https://orcid.org/0000-0002-3149-4408
Urai, Shin https://orcid.org/0000-0002-7996-232X
Kitayama, Shuichi
Bando, Hironori https://orcid.org/0000-0002-7421-2714
Yamamoto, Masaaki
Fukuoka, Hidenori https://orcid.org/0000-0001-9255-653X
Ogawa, Wataru https://orcid.org/0000-0002-0432-4366
Kaneko, Shin https://orcid.org/0000-0003-2291-4586
Takahashi, Yutaka https://orcid.org/0000-0002-1337-9246
-
Funding
Funding for this research was provided by:
MEXT | Japan Society for the Promotion of Science (18K08514, 23659477, 21K20933, and 22K16396)
Japan Agency for Medical Research and Development (17bm0804012h0001)
- License Information
-
More Information
Article History
Received: 30 October 2023
Accepted: 13 August 2025
First Online: 25 August 2025
Competing interests
: Yutaka Takahashi has received research funding from Teijin Pharma Co., Ltd. and Ono Pharma Co., Ltd. Shin Kaneko is a founder, shareholder, and director of Thyas Co., Ltd. and has received research funding from Takeda Pharmaceutical Co., Ltd., Astellas Co., Ltd., Kirin Co., Ltd., Terumo Co., Ltd., and Thyas Co., Ltd. The other authors have nothing to declare.
